News about Clinical Trials

Roche's Sefaxersen Cuts Proteinuria in IgA Nephropathy

Roche’s sefaxersen significantly reduces proteinuria in IgA nephropathy, with Phase III IMAgINATION data showing meaningful results versus placebo.

Clinical Trials | 24/09/2026 | By News Bureau

Caliway Reports Positive Phase 2 Results in Dercum's Disease

Caliway Biopharmaceuticals has reported final Phase 2 results showing sustained pain reduction with CBL-514 in patients with Dercum’s disease.

Clinical Trials | 24/09/2026 | By News Bureau

Vertex Reports Positive Phase 2b AMPLIFIED Study Results

Vertex has reported positive phase 2b AMPLIFIED results in additional AMKD populations and has completed enrollment in the phase 2/3 AMPLITUDE trial.

Clinical Trials | 24/09/2026 | By News Bureau

Ionis Reports Positive Phase 3 FUSION Study Results

Ionis reports positive phase 3 FUSION results for ulefnersen, advancing a potential first disease-modifying treatment for FUS-ALS.

Clinical Trials | 24/09/2026 | By News Bureau

Amgen's Dazodalibep Meets Phase 3 OASIZ 301 Goal

Amgen reports positive topline results from the Phase 3 OASIZ 301 study evaluating dazodalibep in adults with Sjögren’s disease and moderate-to-severe systemic disease activity.

Clinical Trials | 23/09/2026 | By News Bureau

Roche Reports Positive Phase 2 Results for Enicepatide

Roche has announced positive phase 2 results for dual GLP-1/GIP receptor agonist enicepatide in people living with Type 2 Diabetes and overweight or obesity.

Clinical Trials | 23/09/2026 | By News Bureau

Teva's Olanzapine LAI Shows Long-Term Schizophrenia Efficacy

Teva’s TEV-’749 olanzapine LAI showed high stabilisation rates, low relapse and long-term remission in a phase 3 SOLARIS trial analysis.

Clinical Trials | 22/09/2026 | By News Bureau

Teva's UZEDY Outperforms LAIs in Schizophrenia Care

Teva Pharmaceuticals shows new real-world data showing UZEDY outperforms other Long-Acting Injectables in treatment adherence, reducing ER visits and costs.

Clinical Trials | 21/09/2026 | By News Bureau

Avacta Reports Early Clinical Validation of AVA6103 in FOCUS-01 Trial

Avacta’s early FOCUS-01 data provide clinical validation for AVA6103 and support further evaluation of its pre|CISION tumour-activated PDC platform.

Clinical Trials | 21/09/2026 | By News Bureau |  234

Longeveron's Laromestrocel Trial Misses Primary Endpoint in HLHS

Longeveron’s investigational stem cell therapy laromestrocel did not meet the primary efficacy endpoint in the Phase 2b ELPIS 2 trial evaluating infants with hypoplastic left heart syndrome.

Clinical Trials | 21/09/2026 | By News Bureau